Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 25;9:17453. doi: 10.1038/s41598-019-53745-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Characterization of CD11b⁺ cells with flow cytometry. PBMCs were stained with antibodies against CD11b, CD33, and HLA-DR on ice for 30 min. After fixation and permeabilization, cells were incubated with an antibody against ARG1 on ice for another 30 min. (a) Stained cells were analyzed using a flow cytometer, which revealed two distinct populations of CD11b⁺/CD33^hi (P4 gate) and CD11b⁺/CD33^lo (P6 gate) cells from BDI patients. The percentages of (b) CD11b⁺/CD33^hi and (c) CD11b⁺/CD33^lo cells between BDI patients and healthy controls (HC) were calculated and adjusted for gender and age using general linear regression (#p < 0.05; ##p < 0.01). Among BDI patients, only the percentage of (c) CD11b⁺/CD33^lo cells differed significantly between rs17026688 T and non-T carriers, as assessed with the Mann-Whitney test (**p < 0.01). These two groups of CD11b⁺ cells were further gated to examine the expression of HLA-DR and ARG1 (d) or of CD14 and CD15 (e). (f) The percentage of ARG1⁺ cells was compared between CD11b⁺/CD33^hi and CD11b⁺/CD33^lo populations in rs17026688 T and non-T carriers among BDI patients and HC using the Mann-Whitney test (*p < 0.05; **p < 0.01). Horizontal lines denote the mean ± SEM.